NVO Stock Recent News
NVO LATEST HEADLINES
Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “2024 was another year of significant growth for Novo Nordisk, characterised by continued innovation, capacity expansions and commercial execution.
This might surprise some, but Danish pharmaceutical giant Novo Nordisk (NVO -2.29%) has significantly lagged the market in the past year. The drugmaker's shares are down by 40% over the trailing-12-month period, despite grabbing headlines for its work in the red-hot weight management drug market.
Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.
Novo Nordisk A/S NVO has been on a tear in the weight loss drug race, but its stock is slimming down for all the wrong reasons.
Markets are rotating away from U.S. stocks, but I'm doubling down on undervalued American companies built to last decades, not chase trends. Political noise and short-term trading dominate headlines, but successful investing means ignoring hype and sticking to quality-forever holdings. My strategy focuses on durable businesses with wide moats, strong cash flows, and dividends - companies that thrive in any market environment.
There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022.
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=138645&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=138604&wire=1 or contact Joseph E. Levi, Esq.
NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the health care system is improving.